Results of a randomized, placebo-controlled, double-blind, 12-week, multicenter study of solriamfetol (JZP-110) for the treatment of excessive sleepiness in patients with obstructive sleep apnea
Introduction: This phase 3 pivotal trial evaluated solriamfetol, a selective dopamine norepinephrine reuptake inhibitor with wake-promoting effects, for the treatment of excessive sleepiness (ES) in patients with obstructive sleep apnea (OSA). ES is a common OSA symptom that can persist and affect activities of daily living despite primary treatment such as continuous positive airway pressure (CPAP) or oral appliances.
Source: Sleep Medicine - Category: Sleep Medicine Authors: P.K. Schweitzer, R. Rosenberg, G.K. Zammit, M. Gotfried, D. Chen, J. Li, L.P. Carter, H. Wang, J. Black, K. Strohl Tags: Excessive Daytime Sleepiness (not Narcolepsy) Source Type: research
More News: Narcolepsy | Obstructive Sleep Apnea | Sleep Apnea | Sleep Disorders | Sleep Medicine | Study